Analysts forecast that Amneal Pharmaceuticals Inc (NYSE:AMRX) will report $403.26 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Amneal Pharmaceuticals’ earnings. The highest sales estimate is $413.50 million and the lowest is $382.50 million. Amneal Pharmaceuticals reported sales of $476.49 million during the same quarter last year, which indicates a negative year over year growth rate of 15.4%. The company is expected to issue its next quarterly earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that Amneal Pharmaceuticals will report full-year sales of $1.67 billion for the current fiscal year, with estimates ranging from $1.62 billion to $1.70 billion. For the next year, analysts expect that the business will report sales of $1.69 billion, with estimates ranging from $1.56 billion to $1.78 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Amneal Pharmaceuticals.

Amneal Pharmaceuticals (NYSE:AMRX) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.09 EPS for the quarter, missing the Zacks’ consensus estimate of $0.14 by ($0.05). The business had revenue of $404.60 million for the quarter, compared to analysts’ expectations of $420.12 million. Amneal Pharmaceuticals had a negative net margin of 3.65% and a positive return on equity of 28.20%. The business’s revenue was down 12.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.24 earnings per share.

AMRX has been the subject of a number of research reports. BMO Capital Markets decreased their target price on shares of Amneal Pharmaceuticals from $6.00 to $5.00 and set a “market perform” rating for the company in a research report on Tuesday, August 6th. Royal Bank of Canada cut shares of Amneal Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $11.00 to $6.00 in a report on Thursday, July 11th. Zacks Investment Research raised shares of Amneal Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday. Raymond James cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and cut their price objective for the company from $13.00 to $8.50 in a report on Wednesday, July 10th. Finally, Barclays set a $5.00 price objective on shares of Amneal Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, July 11th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the company’s stock. Amneal Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $9.00.

In other news, VP Andrew S. Boyer bought 66,666 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were bought at an average cost of $2.89 per share, for a total transaction of $192,664.74. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ted C. Nark bought 50,000 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was purchased at an average price of $2.39 per share, for a total transaction of $119,500.00. The disclosure for this purchase can be found here. Insiders have purchased 1,788,966 shares of company stock worth $5,377,057 over the last 90 days. 26.34% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of AMRX. Point72 Asset Management L.P. acquired a new position in Amneal Pharmaceuticals in the 2nd quarter valued at about $23,772,000. BlackRock Inc. lifted its holdings in shares of Amneal Pharmaceuticals by 9.4% in the 2nd quarter. BlackRock Inc. now owns 6,394,923 shares of the company’s stock worth $45,852,000 after acquiring an additional 549,217 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Amneal Pharmaceuticals by 487.8% in the 1st quarter. Marshall Wace LLP now owns 492,275 shares of the company’s stock worth $6,977,000 after acquiring an additional 408,533 shares during the last quarter. Phocas Financial Corp. acquired a new position in shares of Amneal Pharmaceuticals in the 1st quarter worth approximately $5,331,000. Finally, Nuveen Asset Management LLC acquired a new position in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $2,505,000. Institutional investors own 34.79% of the company’s stock.

NYSE AMRX traded down $0.01 on Tuesday, reaching $3.48. 16,819 shares of the company’s stock traded hands, compared to its average volume of 1,829,185. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of 3.58, a P/E/G ratio of 0.43 and a beta of 1.49. The stock has a 50 day moving average price of $2.93 and a 200-day moving average price of $8.34. Amneal Pharmaceuticals has a fifty-two week low of $2.27 and a fifty-two week high of $24.35. The company has a debt-to-equity ratio of 3.66, a quick ratio of 1.41 and a current ratio of 2.17.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Article: Which market index is the best?

Get a free copy of the Zacks research report on Amneal Pharmaceuticals (AMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.